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(57) ABSTRACT 
Methods and compositions useful for neuronal protection in 
retinal cells in vitro and the protection of mammalian cells 
from reactive oxygen species in vivo are provided. Ultrafine 
nano-size cerium oxide particles, less than 10 nanometers in 
diameter, have been provided to decrease reactive oxygen 
species (ROS) in retina tissue that generates large amounts of 
ROS. These reactive oxygen species (ROS) are involved in 
light-induced retina degeneration and age-related macular 
degeneration (AMD). Cerium oxide nanoparticles have been 
used to promote the lifespan of retinal neurons and protect the 
neurons from apoptosis induced by hydrogen peroxide in 
vitro and in vivo. The neuronal protection in retinal cells is 
achieved by decreasing generation of intracellular reactive 
oxygen species (ROS). Thus, cerium oxide particles are used 
to promote the longevity of retinal neurons in vitro and mam-
malian cells in vivo. 
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INHIBITION OF REACTIVE OXYGEN 
SPECIES AND PROTECTION OF 
MAMMALIAN CELLS 
2 
or outside of the cells. These diseases include all forms of 
blindness whether hereditary, light-induced, or physical dam-
age such as occurs in retinal detachment. In addition, damage 
due to ageing, stroke, cardiac infarction, bums, etc, which 
proceed through reactive oxygen species, can be addressed 
with the nanoceria particles of the present invention. 
This is a Divisional of application Ser. No.: 11/412,665 
filed Apr. 27, 2006 which claims the benefit of priority to U.S. 
Provisional Patent Application No.: 60/676,043 filed Apr. 29, 
2005 and claims benefit of U.S. Provisional Patent Applica-
tion No.: 60/716,630 filed Sept. 13, 2005. 
FIELD OF THE INVENTION 
The present invention promotes a longer lifespan for retinal 
neurons. The greatest benefit of the nanoceria is its ability to 
get inside the cells and provide protection from reactive oxy-
10 gen species (ROS); other body systems and tissues can also be 
protected from damage due to ROS. 
This invention relates to biological uses of nanoceria par-
ticles, and in particular to methods and compositions useful 
for neuronal protection in retinal cells in vitro and the protec- 15 
ti on of mammalian cells from reactive oxygen species in vivo 
and is supported in part by funding from the National Science 
Foundation and National Institutes of Health under the Con-
tract numbers: P20 RR17703, FY014427, FY13050, and 
FY12190. 20 
BACKGROUND AND PRIOR ART 
SUMMARY OF THE INVENTION 
A primary objective of the present invention is to promote 
the lifespan of retinal neurons in culture. 
A secondary objective of the present invention is to protect 
retinal neurons from apoptosis induced by hydrogen peroxide 
(H2 0 2 ) in vitro. 
A third objective of the present invention is to protect 
retinal neurons from apoptosis induced by reactive oxygen 
species in vivo. 
Cerium is a silvery metallic element, belonging to the 
lanthanide group. Cerium Oxide (Ce02 ) is used in precision 
polishing and lapping applications. Ultra fine nano-size 
cerium oxide, less than 10 nanometers, is more efficient for 
coating purposes. Recently, it was reported by B. Rzigalinski 
A fourth objective of the present invention is to inhibit the 
rise in the intracellular concentration of reactive oxygen spe-
25 cies (ROS). 
A fifth objective of the present invention is to provide 
method for inhibiting apoptosis induced by H20 2 of retinal 
neurons in vitro in a dose and time dependent manner. 
et al. that nanoparticles prolong the life of cortical neurons in 
culture 4 fold over the cells without treatment; decreased the 
intracellular Ca2+ concentration and prevented UV damage 
A sixth objective of the present invention is to provide 
30 method for inhibiting apoptosis induced by reactive oxygen 
species in retinal neurons in vivo in a dose and time dependent 
of cortical neurons. See B. Rzigalinski et al., "Cerium Oxide 
Nanoparticles Extend Cell Longevity and Act as Free Radical 
Scavengers" at website http://www.med.miami.edu/nmbws/ 
Rzigalinskil 12.html. Based on its chemical characteristics, 35 
this effect is partially due to a decrease of reactive oxygen 
species (ROS). 
Retina tissue generates a large amount of ROS which are 
involved in light-induced retina degeneration and age-related 
macular degeneration (AMD). The present invention tests the 40 
hypothesis that nanoparticles can promote the lifespan of 
retinal neurons in culture and protect them from apoptosis 
induced by hydrogen peroxide (H2 0 2 ) in vitro by decreasing 
the intracellular concentration of reactive oxygen species. 
In 2004, T. H. Margrain et al. discuss the state of research 45 
in the treatment of age-related macular degeneration in 
Progress in Retinal and Eve Research, 2004, 23: 523-531, 
"Do Blue Light Filters Confer Protection Against Age-Re-
lated Macular Degeneration?" The problem of apoptosis in 
the body is discussed in an article by P. Moongkamdi et al. in 50 
"Antiproliferation, Anti oxidation and Induction of Apoptosis 
by Garcinia Mangostana (Mangosteen) on SKBR3 Human 
Breast Cancer Cell Line", Jl. of Ethnopharmacology, 2004, 
90: 161-166. 
manner. 
A seventh objective of the present invention is to provide a 
method for preventing an increase in the intracellular reactive 
oxygen species (ROS) in a dose and time dependent manner. 
An eighth objective of the present invention is to manufac-
ture and modify cerium oxide (Ce02 ) nanoparticles for effec-
tive use in neuronal protection in retinal cells. 
A ninth objective of the present invention is to manufacture 
and modify cerium oxide (Ce02 ) nanoparticles for effective 
use in manimalian cells in vivo to inhibit damage caused by 
reactive oxygen species (ROS). 
A preferred composition for promoting longevity of retinal 
neurons includes at least one ofCeO.sub.nl wherein O<nl <2, 
and O<n2<3 in the form of ultra-fine particles. The preferred 
ultra-fine particles have a diameter in a range between 
approximately 1 nanometer (nm) and approximately 10 nm 
and the preferred CeO.sub.nl is further defined as nl equals 
approximately 2. 
A preferred composition for inhibiting apoptosis induced 
by hydrogen peroxide oxidation of retinal neurons includes at 
least one of CeO.sub.nl wherein O<nl <2, and O<n2<3 in the 
form of ultra-fine particles. The preferred ultra-fine particles 
have a diameter in a range between approximately 1 nanom-
Often persons suffering from light-induced retina degen-
eration and age-related macular degeneration (AMD) are 
without satisfactory remedies to prevent the eventual out-
come of blindness. There are some proteins available for 
neuronal protection of retinal cells, however, they are big 
molecules and over time their effect may fade away. 
55 eter (nm) and approximately 10 nm and the preferred CeO-
.sub.nl is further defined as nl equals approximately 2. 
It is desirable to find reliable solutions to prolong the 
lifespan of retinal neurons so that blindness is avoided for 
persons with retina degeneration and AMD. 
In addition to diseases of the eye, many human diseases are 
due to the death of cells in specific tissues or organs. The 
majority of those diseases are due to accumulation of meta-
bolic insults from reactive oxygen species originating within 
A preferred composition for inhibiting apoptosis of retinal 
neurons in a dose and time dependent manner includes at least 
one ofCeO.sub.nl wherein O<nl <2, and O<n2<3 in the form 
60 ofultra-fine particles. The preferred ultra-fine particles have a 
diameter in a range between approximately 1 nanometer (nm) 
and approximately 10 nm and the preferred CeO.sub.nl is 
further defined as nl equals approximately 2. 
A more preferred composition that decreases the concen-
65 tration of intracellular reactive oxygen species (ROS) 
includes at least one of CeO.sub.nl wherein O<nl <2, and 
O<n2<3 in the form of ultra-fine particles. The more preferred 
US 7,727,559 B2 
3 
composition is used in the treatment of diseases of the retina 
selected from the group consisting of light-induced retina 
degeneration and age-related macular degeneration, and is 
also used in vivo for the treatment of diseases in mammalian 
cells to inhibit damage caused by reactive oxygen species 
(ROS). 
4 
nanoparticles for time periods between approximately 12 
hours and approximately 96 hours. 
FIG. 6 shows the initial cerium oxide nanoparticle treat-
ments, hydrogen peroxide and DCFH-DA incubation, and 
time line of exposure. 
FIG. 7A is a graph of the intracellular level of reactive 
oxygen species (ROS) of retinal neurons after 30 minutes 
incubation with cerium oxide nanoparticles. 
The mammalian cells that can be treated by the composi-
tion of the present invention, include, but are not limited to, 
retinal neurons, brain cells, heart cells, skin cells, liver cells, 
kidney cells and peripheral nervous system cells. 
FIG. 7B is a graph of the intracellular level of reactive 
1 o oxygen species (ROS) of retinal neurons after 12 hours incu-
bation with cerium oxide nanoparticles. A preferred method for promoting longevity of retinal 
neurons includes preparing ultra-fine particles of at least one 
ofCeO.sub.nl wherein O<nl <2, and O<n2<3 in a preselected 
concentration, and adding the preselected concentration of 
CeO.sub.nl wherein O<nl <2, and O<n2<3 to primary retinal 15 
neurons. The preferred ultra-fine particles have a diameter in 
a range between approximately 1 nanometer (nm) and 
approximately 10 nm and the CeO.sub.nl is further defined as 
FIG. 7C is a graph of the intracellular level of reactive 
oxygen species (ROS) ofretinal neurons after 24 hours incu-
bation with cerium oxide nanoparticles. 
FIG. 7D is a graph of the intracellular level of reactive 
oxygen species (ROS) ofretinal neurons after 96 hours incu-
bation with cerium oxide nanoparticles. 
nl equals approximately 2. The preferred preselected con-
centrations of Ce02 are in a range between approximately 3 20 
nanomolar (nM) and approximately fifty nanomolar (nM), 
more preferably in a range between approximately 3 nano-
molar (nM) and approximately twenty nanomolar (nM). 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
It is also preferred that the preselected concentrations of 
Ce02 are added to primary retinal neurons in vitro and/or 25 
administered to mammalian cells in vivo to protect the mam-
malian body system from damage to any tissue due to reactive 
oxygen species (ROS). 
for the purpose of description and not of limitation. 
The present invention has two embodiments describing in 
detail the in vitro and in vivo treatment of mammalian cells 
with ultra fine nano-size cerium oxide particles, less than 10 
nanometers in diameter, to protect the "body system" from 
damage to any tissue due to reactive oxygen species (ROS). 
Further objects and advantages of the present invention 
will be apparent from the following detailed description of a 30 
presently preferred embodiment which is illustrated sche-
matically in the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a timeline of exposure of a primary retinal neuron 
culture to treatment with cerium oxide nanoparticles. 
FIG. 2 is a graph showing the percentage of apoptotic 
retinal neurons in culture with and without 5 nanomoles (nM) 
cerium oxide nanoparticle treatment at different time points. 
FIG. 3 shows the initial cerium oxide nanoparticle treat-
ments followed by hydrogen peroxide incubation, and time 
line of exposure. 
FIG. 4A is a flow cytometry plot of the control sample of 
primary retinal neurons with no cerium oxide nanoparticle 
treatments and no hydrogen peroxide incubation. 
FIG. 4B is a flow cytometry plot ofretinal neurons in the 
presence of 100 micromoles (µM) hydrogen peroxide. 
FIG. 4C is a flow cytometry plot of retinal neurons treated 
with 1 nM cerium oxide in the presence of 100 
micromoles (µM) hydrogen peroxide. 
FIG. 4D is a flow cytometry plot of retinal neurons treated 
with 3 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
Hydrogen peroxide (H2 0 2 ) is one of many reactive oxygen 
species. In the present invention, H2 0 2 is added directly to 
35 cultures for the in vitro treatments. H2 0 2 is not added to the 
live tissue samples, since H2 0 2 is one of the ROS products of 
light damage. The discussion below confirms that nanoceria 
particles inhibit all forms ofreactive oxygen species (ROS). 
For example, the nanoceria particles of the present inven-
40 tion can protect the brain against stroke and reperfusion 
injury, the heart cells from effects of cardiac infarction, the 
skin from UV rays and bum injuries. Neurodegeneration 
(e.g., Alzheimer's, Parkinson's, dementia, amyotrophic lat-
eral sclerosis) and potentially mental retardation (due to loss 
45 of brain cells) within the central and peripheral nervous sys-
tems can also be inhibited. This protection can extend to 
diseases which produce chronic problems such as cirrhosis of 
the liver or kidney or the multi-organ effects of aging itself. 
The nanoceria can become the universal treatment for all 
50 major and minor diseases and events which involve reactive 
oxygen species. 
The nanoceria (Ce02 nanoparticles) have the ability to 
FIG. 4E is a flow cytometry plot ofretinal neurons treated 55 
with 5 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
destroy toxic products of metabolism known as reactive oxy-
gen species (ROS). It has been shown in one embodiment that 
the nanoceria particles prevent the ROS induced death of 
mammalian retinal neurons in culture (in vitro) and subse-
quently prolonged the life of the cells in culture and protected 
the cells from ROS. In the second embodiment, the ability to 
provide mammalian cell protection in vivo is disclosed. 
FIG. 4F is a flow cytometry plot ofretinal neurons treated 
with 10 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
FIG. 4G is a flow cytometry plot ofretinal neurons treated 
with 20 nM cerium oxide in the presence of 100 micromoles 
(µM) hydrogen peroxide. 
FIG. 4H is a flow cytometry plot of retinal neurons treated 
with 20 nM cerium oxide. 
FIG. 5 shows relative viable retinal neurons with and with-
out incubation of different concentrations of cerium oxide 
60 The first embodiment of the present invention provides a 
method and composition for promoting the lifespan of retinal 
neurons and protecting the nerve cells in the eye from apop-
tosis induced by hydrogen peroxide (H20 2 ) in vitro by 
decreasing generation of intracellular reactive oxygen spe-
65 cies. The treatment of the eye with ultra fine nano-size cerium 
oxide is a significant advance in biological uses of cerium 
oxide. Persons afflicted with such conditions as, light-in-
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duced retina degeneration and age-related macular degenera-
tion (AMD) have hope for brighter, clearer vision. 
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C3 represents the percentage of 10,000 cells showing nei-
ther Annexin V nor PI positive signals, which is interpreted as 
the percentage of 10,000 cells which are still viable. The examples below provide further detail on the prepara-
tion and treatment of retinal nerve cells with Ce02 nanopar-
ticles. 
C4 represents the percentage of 10,000 cells showing a PI 
5 positive signal, which is interpreted as the percentage of 
10,000 cells in a necrotic stage. 
EXAMPLE 1 Quadrants C2 and C4 show the percentage of 10,000 cells 
committed to die. In quadrant Cl the percentage of 10,000 
cells undergoing apoptosis are shown and some may be sal-
10 vaged. It is important to observe the percentage of 10,000 
cells in quadrant C2 for the efficacy of the cerium oxide 
treatment of the present invention. 
A primary retinal neuron culture is obtained from albino rat 
pups. Retinae of Sprague-Dawley albino rat pups (0-2-day 
old) were dissected out and mechanically dissociated in 25 ml 
ofDMEM/F12 medium. After being filtered through 230 µm 
and 140 µm sieves, the dissociated cells were centrifuged at 
1200 rpm for 5 min. The cell pellets were re-suspended in the 
medium to 1xl05 cells/ml. 1 ml of the cell suspension was 
plated in each well pre-treated with 10 µg/ml of poly-D-
lysine. The cells were maintained in the medium until day 7, 
when different concentrations of Ce02 nanoparticles were 
added to the cultures. The timeline for the addition ofCe02 
nanoparticles is shown in FIG. 1. The treated neuronal cells 20 
were harvested on day 14, day 19, day 24 and day 29 after the 
beginning of treatment on day 7. The percentage of apoptotic 
retinal neurons in the culture with and without 5 nM Ce02 
nanoparticle treatment is shown in FIG. 2 at the 12th day, 14th 
day, 19 h day, 24th day and 29th day. Data are shown in 25 
M±S.D. Statistics were collected by Student t-test (n=3, 
*p<0.05, **p<0.01). FIG. 2 confirms that at every testing 
period the control with no Ce02 nanoparticle treatment had a 
higher percentage of apoptotic retinal neurons in the culture, 
Focusing on the viable cells, the control in FIG. 4A has no 
Ce02 nanoparticle treatment and 73.9% of the cell population 
15 is viable after 96 hours. FIG. 4B is treated with 100 µM H20 2 , 
causing a deadly assault and leaving the lowest percentage 
(57 .7%) of viable cells. The addition of gradually increasing 
concentrations of cerium oxide with 100 µM H20 2 , are shown 
in contrast to the decreased percentage of apoptotic retinal 30 
neurons in the cells treated with 5 nM Ce02 nanoparticles. 
EXAMPLE2 
The detection of apoptosis by flow cytometry is illustrated 35 
in FIGS. 3, 4A-4H and 5. After periods of incubation with 
Ce02 or H20 2 , the cells were washed with serum free 
medium 3 times, followed by treatment of 1 ml of 1 xtrypsin 
for 2 min. After centrifuging, the cell pellet was resuspended 
in 500 µl of 1 xPBS containing 5 µl of Annexin V-FITC and 25 40 
µl of Propidium Iodide (PI). The kit used for the analysis is 
commercially available from Beckman Coulter and is known 
as the "ANNEXIN V-FITC Kit." The mixture was incubated 
in FIGS. 4C-4G. 
FIG. 4C is treated with 1 nM Ce02 nanoparticles and 100 
µM H2 0 2 and 60.6% of the cell population remains viable. 
FIG. 4D is treated with 3 nM Ce02 nanoparticles and 100 µM 
H2 0 2 and 67.0% of the cell population is viable. FIG. 4E is 
treated with 5 nM Ce02 nanoparticles and 100 µM H20 2 , with 
68.9% of the cell population remaining viable. FIG. 4F is 
treated with 10 nM Ce02 nanoparticles and 100 µM H2 0 2 and 
72.6% of the cell population is viable. FIG. 4G is treated with 
20 nM Ce02 nanoparticles and 100 µM H2 0 2 and 72.3% of 
the cell population remains viable. 
FIG. 4H is treated with 20 nM Ce02 nanoparticles without 
the addition ofH2 0 2 and 73 .4% of the cell population remains 
viable showing that the Ce02 nanoparticles alone have no 
negative effect on the cell population. 
The data in FIGS. 4A-4H can also be summarized from the 
analysis of cells undergoing apoptosis as shown in quadrant 
Cl. The control, FIG. 4A shows 16.2% of cells undergoing 
apoptosis under normal conditions, without any treatment, 
after 96 hours. FIG. 4B shows 26.1 % of cells undergoing 
apoptosis after the 100 µM H2 0 2 challenge. FIGS. 4C-4G 
show there are 28.3%, 21.9%, 22.2%, 18.5% and 15.8% of 
cells undergoing apoptosis with 1, 3, 5, 10 and 20 nM Ce02 
nanoparticle treatment, respectively. FIG. 4H shows 15 .7% of 
cells undergoing apoptosis with 20 nM Ce02 nanoparticle on ice for 10 minutes. The fluorescent emissions ofFITC and 
PI were detected by flow cytometry (Beckman Coulter) with 
the excitation filters of 492 nanometers (nm) and 550 nm. The 
FITC fluorescent emissions signals the presence of cells 
undergoing apoptosis; whereas, the PI signals with an auto-
matic red color fluorescence the binding to DNA fragments 
identifying cells in a necrotic stage. 
45 treatment, which is a slight improvement over no treatment at 
all as shown by the control in FIG. 4A. 
Thus, cerium oxide nanoparticles inhibit apoptosis in reti-
nal neurons in vitro in a dose and time dependent manner. 
FIG. 5 shows relative viable retinal neurons with and with-
FIG. 3 shows a treatment timeline with Ce02 incubation 
after the 7th day of treatment at the time intervals of 12 hours, 
24 hours, 72 hours and 96 hours with each treated sample 
subsequently exposed to 12 hours incubation time with H20 2 . 
50 out incubation of different concentration of Ce02 nanopar-
ticles for different time periods. The concentration of Ce02 
nanoparticles were 1 nM, 3 nM, 5 nM, 10 nM, 20 nM each 
with 100 µMH 2 0 2 ; one sample was treated with only 100 µM 
FIGS. 4A-4H are representative flow cytometry plots of 55 
retinal neurons with and without incubation with Ce02 nano-
particles. Measurements were taken after 96 hours. The 
cytometry plot shows activity of approximately 10,000 cells 
in four quadrants, as described below. 
Cl represents the percentage of 10,000 cells showing 60 
Annexin V positive signals, which are interpreted to indicate 
the percentage of 10,000 cells undergoing apoptosis. 
C2 represents the percentage of 10,000 cells showing both 
Annexin V and PI positive signals, which is interpreted as the 
percentage of 10,000 cells which are in late apoptotic or 65 
necrotic stage. (Annexin V signals apoptotic stage; PI signals 
necrotic stage.) 
H2 0 2 and another sample was treated with only 20 nM Ce02 
nanoparticles. The measurement of relative viable cells for 
each group was determined after 12 hours, 24 hours, 48 hours, 
72 hours and 96 hours. The effects showed dose and time 
dependency. 
5 nM cerium oxide nanoparticles started to decrease the 
apoptosis at 24 h of incubation. As incubation time increased, 
the protective effect from 5 nM nanoparticles was more sig-
nificantly increased. Additionally, 10 nM and 20 nM nano-
particles began to have effects late with 96 h of incubation. 
(Statistical analysis was done by ANOVA, and Duncan test 
for post hoc analysis. Data are presented in M±S.D. n~3, 
*p<0.05, **p<0.01). FIG. 5 shows that among the various 
treatment doses, 5 nM Ce02 nanoparticle treatment gave the 
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earliest response with moderate protective effect and 20 nM 
Ce02 nanoparticle treatment gave the highest protective 
effect with late response. 
EXAMPLE3 
Intracellular reactive oxygen species (ROS) production 
was measured in both Ce02 nanoparticle treated and control 
cells using 29,79-dichlorofluorescein diacetate (DCFH-DA, 
Sigma). Briefly, the retinal neurons were exposed to Ce02 10 
nanoparticles with different concentrations and various incu-
bation times. After incubation, the cells were incubated with 
10 µM DCFH-DA (dissolved in dimethy lsulfoxide (D MSO)) 
at 3 7° C. for 30 min. The cells then were incubated with 1 mM 
H2 0 2 at 37° C. for 30 min after the excess DCFH-DA was 15 
washed with PBS. The cells were harvested as described 
8 
an insult, is important. Thus, the nanoceria will also prevent 
the death ofretinal cells due to glaucoma, diabetic retinopa-
thy, inherited retinal degeneration (for example, Retinitis Pig-
mentosa), macular degeneration, retinal detachment or any 
disease or event which proceeds through the production of 
ROS. These particles should preserve and prolong vision 
when administered in vivo. 
EXAMPLE4 
Rats were injected intravitreally with 2 microliters (µl) of 
nanoceria (concentrations from 0.1 to 1.0 micromolar) three 
days before they were exposed for six hours to a bright light 
(2700 LUX) in a light box. The animals were returned to 
normal lighting for3.5 days, then killed, the eyes enucleated, 
fixed, processed for paraffin embedding, sectioned, and either 
stained with H & E or processed for immunocytochemistry. 
The number of photoreceptors remaining was determined 
with the H&E sections by using a microscope connected to a 
above. The intensity of fluorescence was detected by flow 
cytometry with the excitation filter of 485 nm. The ROS level 
was calculated as a ratio: ROS=mean intensity of treated cells 
divided by mean intensity of control cells. 
FIG. 6 is an experimental paradigm showing the beginning 
of the Ce02 nanoparticle treatment on the 7th day and simul-
taneous incubation with H20 2 and DCFH-DA and a timeline 
20 digital camera to record the images and then measuring the 
thickness of the outer nuclear layer every 240 microns from 
the optic nerve along both the superior and the inferior retina 
to the ora seratta. The data was then plotted as retina thickness 
versus the distance from the optic nerve head. The changes in of exposure at 30 minutes, 12 hours, 24 hours, and 96 hours. 
FIGS. 7A-7D show how the Ce02 nanoparticles decreased 
the generation of ROS in a dose and time dependent manner. 
The ROS generated in the groups of 5 nM, 10 nM, and 20 nM 
nanoparticle incubation were statistically significantly less 
than the group without treatment at the earliest (12 h) of the 
tested points. 3 nM nanoparticle incubation had an effect at 24 30 
h. However, 1 nM nanoparticles did not show any significant 
decrease within the tested time point. Statistical analysis was 
done by AN OVA, and Duncan test for post hoc analysis. Data 
were shown in M±S.D. n=3, **p<0.01; *p<0.05. 
25 other layers of retinal cells were recorded with images but not 
quantified. Cells actively undergoing apoptosis were also 
visualized using a commercially available "Apoptosis kit" 
and recording the microscopic images with a fluorescence 
The cerium oxide of the present invention includes those 35 
cerium compounds that have reacted with atmospheric oxy-
gen to have stable oxide layers identified as CeO.sub.nl, 
wherein 0 is less than 1 or equal to 2 (O<nl <2) and (O<n2<3). 
The cerium oxide particles of the present invention are 
characterized as ultra-fine and are preferably in a size range of 40 
from approximately 1 nanometer in diameter to approxi-
mately 10 nanometers in diameter; more preferably from 
approximately 1 nm to approximately 7 nm. A judicious 
selection of particle size is required by someone skilled in the 
microscope. 
The data demonstrate that the nanoceria at all concentra-
tions tested prevented the immediate death of retinal cells 
shortly after exposure to light as well as the ongoing death 
seen days later in the untreated animals. We therefore have 
demonstrated in vivo that these nanoceria particles can pro-
tect cells within the rat retina from light-induced cell death. 
Prior to the present invention, it was not known that nano-
ceria particles could be used in vivo for preventing blindness 
or death of retinal cells, or for preventing the death in vivo of 
any other cell type in any disease. The chemical properties of 
Ce02 nanoparticles enable the destruction of reactive oxygen 
species (ROS) produced by toxins and/or products of oxygen 
metabolism within cells. 
Thus, nanoceria can protect any cell type from ROS 
induced damages. Diseases which could possibly be pre-
art and is not a limitation of the present invention. 
The results of testing in the above examples document the 
ability of cerium oxide nanoparticles to promote the longevity 
45 vented, cured or ameliorated would include hereditary blind-
ness, macular degeneration, glaucoma, diabetic retinopathy, 
retinal detachment, and other blinding diseases which involve 
ROS would be potentially solved. Similarly, in other cells of retinal neurons in vitro and inhibit apoptosis induced by 
hydrogen peroxide on retinal neurons in vitro in a dose and 
time dependent manner. It has also been determined that 50 
cerium oxide nanoparticles decrease generation of intracel-
lular reactive oxygen species in a dose and time dependent 
manner. Thus, the present invention represents a significant 
advance in the treatment in degenerative diseases of the 
retina, such as, but not limited to light-induced retina degen- 55 
eration and age-related macular degeneration (AMD). 
In the second embodiment of the present invention a rat 
"light damage" model for retinal degeneration was used as the 
test system. The data demonstrate that the nanoceria pre-
vented the death of retinal neurons when given prior to the 60 
"light insult". The nanoceria particles protected the cells at 
the time of exposure as well as prevented the subsequent 
death seen days later in the untreated animals. The in vivo 
route of administration, including, direct injection into the 
eye, intravenous, intraperitoneal, intramuscular, oral or topi- 65 
cally on the eye or skin may improve the result. Similarly, the 
time of administration of the nanoparticle, both before or after 
within the central nervous system (CNS), neuronal death in 
strokes, degenerative diseases such as Alzheimer's Disease, 
Parkinson's, Huntington's Disease, and the death of periph-
eral nerves are preventable or at least the rate of cell death can 
be decreased and would result in prolonged function of the 
cells, tissues, organs, and individual. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
and scope of the claims here appended. 
We claim: 
1. A composition of matter consisting essentially of a plu-
rality of nanoceria particles in contact with isolated retinal 
neurons wherein the plurality of nanoceria particles com-
prises atleastoneofCe02 andCe2 0 3 in theformofa plurality 
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of ultra-fine particles, wherein each particle has a diameter in 
a range between approximately 1 nanometer (nm) and 
approximately 10 nm, and the combination of the plurality of 
nanoceria particles in contact with isolated retinal neurons 
inhibits apoptosis of the isolated retinal neurons in a dose and 
time dependent manner. 
10 
2. The plurality ofnanoceria particles in contact with iso-
lated retinal neurons of claim 1, wherein the dosage amount is 
selected from at least one of3 (nanomole) nM, 5 nM, 10 nM, 
and 20 nM ofnanoceria particles. 
* * * * * 
